InvestWiser

SpectraCure AB

SPECNasdaq StockholmHealthcareMarket value 9 m SEK
0.01SEK −6.0%
last day · Price as of 18 November 2026

The answer first

Does SpectraCure beat the market?

No, SpectraCure has not beaten the market over the last year.

SpectraCure−90.6%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 27% of Nordic stocks

    • Quality58
    • Value58
    • Trend1

    No. 113 of 195 in healthcare

Max for seven days

Follow SpectraCure with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on SpectraCure

From today, at a price of 0.01 SEK. Write why you follow SpectraCure, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about SpectraCure

Your first answer is free, no account needed.

Do you own SpectraCure, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with SpectraCure and a few more. Free, no card.

Past year against the exchange and Super Stock
SpectraCure−90.6%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • SpectraCure has fallen 90.6% over the past year, including dividends.
  • Overall, SpectraCure ranks better than 27% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.3%. The price is 99.9% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

27

Quality, value and trend together. Better than 27% of Nordic stocks.

No. 113 of 195 in healthcare

Quality58
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 113 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.13
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−59.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value58
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 34 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.1
  • P/SPrice divided by sales39.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend1
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 193 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−67.7%
  • 6 months−82.2%
  • 9 months−83.8%
  • 12 months−90.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−18.7%
3 years, per year
−78.1%
5 years, per year
−66.0%
10 years, per year
−25.5%
Largest fall, 3 years
−99.3%
From a peak to the bottom
From the peak now
−99.9%
How far the price is from the peak
Volatility, 1 year
113.7%
How much the price swings over a year
Beta, 1 year
0.08
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own SpectraCure

One fund we follow owns SpectraCure. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About SpectraCure

SpectraCure AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 13 employees.

SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.

See the full analysis of SpectraCure.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market